|
|
|
|
|
|
| PSMA PET for Primary Staging (High-Risk Localized, N1, M1)
|
| Thomas Hope, MD, Bertrand Tombal, MD, Ph.D., Nicola Fossati, MD, FEBU, and Robert Reiter, MD
|
| In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs. Thomas Hope, Nicola Fossati, Robert Reiter, and Bertrand Tombal discuss a series of five cases focusing on how PSMA-PET impacts the management of prostate cancer patients.
|
|
|
|
|
|
|
|
|
|
|
|
| PSMA PET Before and After PSMA Radioligand Therapy (Mismatch Example Liver Mets) PSMA PET for Response Monitoring
|
| Prof. Dr. med. Bernd J. Krause and Oliver Sartor, MD
|
| In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs. Oliver Sartor and Bernd Krause discuss PSMA-PET/CT before and after PSMA radioligand therapy with mismatch example for liver metastases.
|
|
|
|
|
|
|
|
|
|
| Pitfalls and Controversial Cases with PSMA PET CT
|
| Stefano Fanti, MD, Christopher Sweeney, MBBS, and Neal Shore, MD, FACS
|
| In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs. Stefano Fanti, Christopher Sweeney, and Neal Shore discuss a controversial topic on what to do when you have bone findings at PSMA PET with no CT counterpart.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reading and Reporting a PSMA PET Scan for Staging Prostate Cancer
|
| Andrea Farolfi, MD
|
| In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Andrea Farolfi presents the clinician's view on reading and reporting a PSMA PET scan. He highlights the PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE) as well as PSMA PET progression criteria (PPP) to define prostate cancer progression by PSMA PET and what is important in a PSMA PET report.
|
|
|
|
|
|
|
|
|
|
|
|
| PSMA PET in the Metastatic Castration-Resistant Prostate Cancer Setting
|
| Oliver Sartor, MD
|
| In this educational initiative, focusing on the knowledge of PSMA PET and PSMA treatment, Oliver Sartor presents PSMA PET in the metastatic castration-resistant prostate cancer setting with the goal of treatment and an outlook on PSMA therapy. He focuses on this in the context of The VISION Trial: Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| Understanding Physiological PSMA Biodistribution
|
| Jeremie Calais, MD, MSc
|
| In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Jeremie Calais presents on understanding the physiological PSMA biodistribution and the pathological uptake of the use of PSMA for prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
| The Mechanism of PSMA PET for Prostate Cancer
|
Stefano Fanti, MD and Ken Herrmann, MD, MBA
In this educational initiative, Stefano Fanti and Ken Herrmann join together to share their knowledge of PSMA PET and PSMA theranostics focusing on the mechanism of PSMA PET imaging, different PET tracers, differences between FDG-PET and PSMA-PET, as well as the concept of PSMA and theranostics.
|
|
|
|
|
|
|
|
|
|
|
| How to Perform a PSMA PET Scan
|
Wolfgang Fendler, MD and Stephan Himmen, MD
In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Drs. Wolfgang Fendler and Stephan Himmen jointly present "How to Perform a PSMA PET Scan.
|
|
|
|
|
|
|
|
|
|
|
| The Dark Side of PSMA: Pitfalls, Limits, and ADT
|
Matthias Eiber, MD, PhD and Thomas Langbein, MD
In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Drs. Matthias Eiber and Thomas Langbein jointly prepared and Dr. Eiber presents on the Dark Side of PSMA: Pitfalls, Limits, and ADT for prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Pluvicto™ (177Lu-PSMA-617) Indications for Clinical Use in PSMA Positive Metastatic Castration-Resistant Prostate Cancer mCRPC
|
Phillip Koo, MD, FACS and Oliver Sartor, MD
Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive mCRPC.
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
